liraglutide glp 1 analogue FDA Approves First Generic Once-Daily Injection Generic Liraglutide (Victoza) Becomes First

Research published in the last week revealed that for the first time in more than a decade, obesity rates among US adults fell slightly last year, decreasing from 46% in 2022 to 45.6% in 2023

Moreover, biomarker-guided patient stratification, functional imaging endpoints, and iPSC-based modelling will be crucial for translating riboflavin biology into clinical efficacy across broader neurological contexts

Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, et al (2022) GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art

What Medicare Covers in 2026 Medicare Part D: Select anti-obesity medications are now covered for beneficiaries who meet specific clinical criteria

It makes it a good fit for a specific pattern

Increased susceptibility to apoptosis and growth arrest of human breast cancer cells treated by a snake venom-loaded silica nanoparticles